

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: WARF-0003  
Inventors: Dickerson et al.  
Serial No.: 09/801,485  
Filing Date: March 8, 2001  
Examiner: Not yet assigned  
Group Art Unit: Not yet assigned  
Title: Compositions and Methods for Targeting  
Interleukin-12 to Malignant Endothelium

"Express Mail" Label No. EV215113154US  
Date of Deposit - December 4, 2002

I hereby certify that this paper is being deposited with  
the United States Postal Service "Express Mail Post Office  
to Addressee" service under 37 CFR 1.10 on the date  
indicated above and is addressed to the U.S. Patent and  
Trademark Office Box Sequence, P.O. Box 2327  
Arlington, VA 22202

By Kathleen A. Tyrell  
Typed Name: Kathleen A. Tyrell

U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

Sir:

RESPONSE TO NOTICE TO COMPLY

In response to the "Notice to Comply" dated October 11,  
2002, a response to which is due December 11, 2002, enclosed  
herewith is:


( ) Amendment under 1.825;

(XX) Statement to Support Filing and Submission in  
Accordance with 37 CFR §§1.821 through 1.825;

- ( ) Substitute pages of the Sequence Listing;
- (XX) Substitute copy of the computer readable form of Sequence Listing;
- (XX) Copy of Notice to Comply;
- ( ) Petition for One (1) Month Extension of Time;
- ( ) Other:\_\_\_\_\_.

The Commissioner is hereby authorized to charge any underpayment associated with this communication or credit any overpayment to Deposit Account No. 50-1619. This sheet is attached in duplicate.

Respectfully submitted,

  
Kathleen A. Tyrrell  
Registration No. 38,350

Date: December 4, 2002

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515



#9

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: WARF-0003  
Inventors: Dickerson et al.  
Serial No.: 09/801,485  
Filing Date: March 8, 2001  
Examiner: Not yet assigned  
Group Art Unit: Not yet assigned  
Title: Compositions and Methods for Targeting  
Interleukin-12 to Malignant Endothelium

"Express Mail" Label No. EV215113154US  
Date of Deposit - December 4, 2002

I hereby certify that this paper is being deposited with  
the United States Postal Service "Express Mail Post Office  
to Addressee" service under 37 CFR 1.10 on the date  
indicated above and is addressed to the U.S. Patent and  
Trademark Office Box Sequence, P.O. Box 2327  
Arlington, VA 22202

By Kathleen A. Tyrell  
Typed Name: Kathleen A. Tyrell

U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202


Sir:

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE  
WITH 37 CFR §§ 1.821 THROUGH 1.825**

- ( ) I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
- ( ) I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
- ( ) I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.

- ( ) I hereby state that any amendments, made in accordance with **37 CFR §1.825(a)**, included in the substitute sheet(s) of the Sequence Listing were made to merely to correct inadvertent typographical errors. I hereby state that the substitute sheet(s) of the Sequence Listing does not include new matter.
- ( ) I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(b)**, is the same as the amended Sequence Listing submitted herewith.
- (XX) I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(d)**, contains identical data to that originally filed and does not include any new matter.

Respectfully submitted,



Kathleen A. Tyrrell  
Registration No. 38,350


Date: December 4, 2002

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515



UNITED STATES  
PATENT AND  
TRADEMARK OFFICE



Commissioner for Patents  
Washington, DC 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/801,485	03/08/2001	Erin B. Dickerson	WARF-0003

26259  
LICATLA & TYRRELL P.C.  
66 E. MAIN STREET  
MARLTON, NJ 08053

CONFIRMATION NO. 4744

**FORMALITIES LETTER**



\*OC000000008944500\*

Date Mailed: 10/11/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

**PART 2 - COPY TO BE RETURNED WITH RESPONSE**